- Home
- CVKD vs INTS Comparison
CVKD vs INTS Comparison
Compare CVKD & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVKD | INTS |
|---|---|---|
| Founded | 2022 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 19.2M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CVKD | INTS |
|---|---|---|
| Price | $4.99 | $6.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $32.00 | ★ $56.25 |
| AVG Volume (30 Days) | ★ 44.9K | 28.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.22 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.91 | $0.19 |
| 52 Week High | $19.03 | $8.06 |
Technical Indicators
Market Signals| Indicator | CVKD | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 27.71 | 52.90 |
| Support Level | N/A | $0.29 |
| Resistance Level | $14.21 | $8.06 |
| Average True Range (ATR) | 0.63 | 0.45 |
| MACD | -0.30 | -0.34 |
| Stochastic Oscillator | 3.96 | 11.76 |
Price Performance
Historical ComparisonAbout CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About INTS Intensity Therapeutics Inc.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.